A review of recent studies of angiotensin II receptor blockers in hypertension, acute myocardial infarction, heart failure, and nephropathy provide some data on specific drugs, doses, and risk ...
The OPtimal Trial In Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL ... which may be of importance when comparing it with a drug-dosed three times daily.
Abstract The purpose of this study was to assess the inhibitory effect of TCV-116, an orally active angiotensin II (Ang ... and long-lasting antagonist of Ang II in men. TCV-116, a new AT 1 receptor ...
Newer drugs act on the renin–angiotensin ... In terms of branded sales, the angiotensin II receptor blocker class dominates with five of the top ten antihypertensives belonging to this class ...
a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide ...
A recent study from Columbia University has raised important questions about the medications used to treat high blood ...
Stockhead on MSN11d
First paediatric patient recruited for Dimerix’s ACTION3 kidney disease drug trialDimerix has achieved a key milestone in its ACTION3 phase III trial of lead asset DMX-200 into focal segmental ...
Abstract We investigated the effects of angiotensin ... feedback Ang II receptor in hypertensive patients produces modest increases of plasma renin activity and Ang II that do not appear to affect the ...
There are currently no drugs currently approved specifically ... with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients ...
Acute coronary syndrome (ACS) is a term used to describe a range of conditions resulting from the sudden reduction or ...
Hosted on MSN28d
Recruitment on track for Dimerix’s global kidney disease trialplacebo-controlled study of the efficacy and safety of DMX200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Planned blinded interim data ...
On January 10, 2025, the US Court of Appeals for the Federal Circuit issued a precedential opinion in Novartis Pharmaceuticals Corp. v. Torrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback